{"id":"NCT01167426","sponsor":"Teva Neuroscience, Inc.","briefTitle":"Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients","officialTitle":"An Open-Label, Multicenter Study Evaluating Patient Injection Satisfaction With Two Formulations of Glatiramer Acetate (GA) Using Autoject 2 as the Subcutaneous Injection Delivery Method.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07","primaryCompletion":"2010-11","completion":"2010-12","firstPosted":"2010-07-22","resultsPosted":"2013-10-17","lastUpdate":"2013-10-17"},"enrollment":148,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":null},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Glatiramer Acetate 20 mg/0.5 mL","otherNames":["CopaxoneÂ®"]},{"type":"DRUG","name":"Glatiramer acetate 20 mg/0.5 mL","otherNames":[]}],"arms":[{"label":"20 mg/0.5 mL Glatiramer Acetate","type":"ACTIVE_COMPARATOR"}],"summary":"This is an open-label, multicenter study conducted at approximately 20 sites. Each patient will inject GA daily for 6 weeks utilizing an autoject 2 device to determine overall injection satisfaction.","primaryOutcome":{"measure":"Change From Week 2 to Week 6 in Composite Score of Patient Satisfaction With Injection Experience","timeFrame":"Week 2 (prior to first injection with 20 mg/0.5 mL formulation), Week 6 (after 4 weeks of treatment with 20 mg/0.5 mL formulation).","effectByArm":[{"arm":"Glatiramer Acetate","deltaMin":4.1,"sd":0.77}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":148},"commonTop":["Injection site reaction"]}}